Development of a Novel Homogeneous Assay for Remnant Lipoprotein Particle Cholesterol

Hirao, Yuhko; Nakajima, Katsuyuki; Machida, Tetsuo; Murakami, Masami; Ito, Yasuki

doi:10.1373/jalm.2017.024919

Cited by 18 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Triglyceride and cholesterol concentrations in total plasma and lipoprotein fractions as well as in TRL‐C and RLP‐C were analyzed using assays (Denka Seiken, Tokyo, Japan) and the Konelab 60i analyzer (Thermo Fisher, USA). RLP‐C captures lipoproteins not binding with anti‐apoA‐I and anti‐apoB‐100 as remnant lipoproteins . The TRL‐C quantifies cholesterol in both chylomicron remnants, and in VLDL‐IDL particles.…”

Section: Methodsmentioning

confidence: 99%

Role of apolipoprotein C‐III overproduction in diabetic dyslipidaemia

Adiels

Taskinen

Andersson

et al. 2019

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aims: To investigate how apolipoprotein C-III (apoC-III) metabolism is altered in subjects with type 2 diabetes, whether the perturbed plasma triglyceride concentrations in this condition are determined primarily by the secretion rate or the removal rate of apoC-III, and whether improvement of glycaemic control using the glucagon-like peptide-1 analogue liraglutide for 16 weeks modifies apoC-III dynamics.Materials and Methods: Postprandial apoC-III kinetics were assessed after a bolus injection of [5,5,5-2 H 3 ]leucine using ultrasensitive mass spectrometry techniques.We compared apoC-III kinetics in two situations: in subjects with type 2 diabetes before and after liraglutide therapy, and in type 2 diabetic subjects with matched body mass index (BMI) non-diabetic subjects. Liver fat content, subcutaneous abdominal and intra-abdominal fat were determined using proton magnetic resonance spectroscopy.Results: Improved glycaemic control by liraglutide therapy for 16 weeks significantly reduced apoC-III secretion rate (561 ± 198 vs. 652 ± 196 mg/d, P = 0.03) and apoC-III levels (10.0 ± 3.8 vs. 11.7 ± 4.3 mg/dL, P = 0.035) in subjects with type 2 diabetes.Change in apoC-III secretion rate was significantly associated with the improvement in indices of glucose control (r = 0.67; P = 0.009) and change in triglyceride area under the curve (r = 0.59; P = 0.025). In line with this, the apoC-III secretion rate was higher in subjects with type 2 diabetes compared with BMI-matched non-diabetic subjects (676 ± 208 vs. 505 ± 174 mg/d, P = 0.042). Conclusions:The results reveal that the secretion rate of apoC-III is associated with elevation of triglyceride-rich lipoproteins in subjects with type 2 diabetes, potentially through the influence of glucose homeostasis on the production of apoC-III.

show abstract

Section: Methodsmentioning

confidence: 99%

Role of apolipoprotein C‐III overproduction in diabetic dyslipidaemia

Adiels

Taskinen

Andersson

et al. 2019

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…The incremental area under the curve (iAUC) was calculated by subtracting fasting AUC from total AUC. sdLDL-C 5) , LDL-TG 9) , HDL3-C 20) , apoE-rich HDL-C 21) , and remnant-like particle (RLP)-C 22) were measured by the homogeneous method (Denka Co., Ltd. Tokyo, Japan). TRL-C was measured directly by the homogeneous method (Denka Co., Ltd.) using a twostep process where LDL and HDL are degraded, and lipoprotein spectrums from TG-rich lipoproteins (TRLs) to HDL 3) .…”

Section: Methodsmentioning

confidence: 99%

Circadian Rhythm of Subspecies of Low-Density Lipoprotein-Cholesterol and High-Density Lipoprotein-Cholesterol in Healthy Subjects and Patients with Type 2 Diabetes

Hayashi

Goto

et al. 2023

JAT

Self Cite

View full text Add to dashboard Cite

Aims:We established automated assay kits for quantifying small dense low-density lipoprotein (sdLDL)cholesterol (C), LDL-triglyceride (TG), and high-density lipoprotein (HDL)3-C, and apolipoprotein (apo)E-rich HDL-C, and these have been recognized as sensitive biomarkers for predicting coronary artery disease. We investigated the circadian rhythms of these novel lipids to determine if fasting is required to determine basal levels. Methods: Forty-eight inpatients with type 2 diabetes and 19 healthy volunteers were studied. Blood samples were collected at seven time points, which were obtained after an overnight fast, before and 2 h after each meal, and before the next breakfast. sdLDL-C, LDL-TG, remnant-like particle (RLP)-C, TG-rich lipoprotein (TRL-C), HDL3-C, and apoE-rich HDL-C were measured by the homogeneous methods. NonHDL-C, large buoyant (lb) LDL-C and HDL2-C were calculated by subtracting sdLDL-C from LDL-C or HDL3-C from HDL-C, respectively.Results: Serum TG levels were significantly increased after meals in both healthy participants and patients with diabetes. RLP-C and TRL-C were also increased postprandially. LDL-TG, LDL-C, nonHDL-C, HDL2,3-C, and apoE-rich HDL-C did not exhibit significant fluctuation during the day in healthy participants and patients with diabetes. sdLDL-C was slightly increased postprandially in subjects with diabetes (1-2 mg/dl, 3%-9%), though its increase was not significant compared to the baseline (fasting) level. Significant postprandial reduction was observed with LDL-C and lbLDL-C. There was no influence of statin therapy or oral anti-diabetes drugs on the circadian rhythm of LDL-C subspecies.Conclusions: Subtle postprandial increase in sdLDL-C is considered a negligible level in general clinical practice. Fasting is not mandatory to measure basal concentrations of LDL and HDL subspecies.

show abstract

“…CMs are initially secreted into the intestinal lymphatic system and subsequently enter the bloodstream. [11] Within the circulation, CMs acquire apolipoproteins such as apolipoprotein AI, apolipoprotein C-II, apolipoprotein C-III, and apolipoprotein E through high-density lipoproteins. Subsequently aided by apolipoprotein C-II, the CMs bind to LPL, leading to triglyceride hydrolysis and ultimately resulting in the production of residual CM particles and FFA.…”

Section: Definition Metabolism Clinical Significancementioning

confidence: 99%

A significant presence in atherosclerotic cardiovascular disease: Remnant cholesterol: A review

Wang,

Zhang,

et al. 2024

Medicine

View full text Add to dashboard Cite

The current first-line treatment for atherosclerotic cardiovascular disease (ASCVD) involves the reduction of a patient’s low-density lipoprotein cholesterol (LDL-C) levels through the use of lipid-lowering drugs. However, even when other risk factors such as hypertension and diabetes are effectively managed, there remains a residual cardiovascular risk in these patients despite achieving target LDL-C levels with statins and new lipid-lowering medications. This risk was previously believed to be associated with lipid components other than LDL, such as triglycerides. However, recent studies have unveiled the crucial role of remnant cholesterol (RC) in atherosclerosis, not just triglycerides. The metabolized product of triglyceride-rich lipoproteins is referred to as triglyceride-rich remnant lipoprotein particles, and its cholesterol component is known as RC. Numerous pieces of evidence from epidemiological investigations and genetic studies demonstrate that RC plays a significant role in predicting the incidence of ASCVD. As a novel marker for atherosclerosis prediction, when LDL-C is appropriately controlled, RC should be prioritized for attention and intervention among individuals at high risk of ASCVD. Therefore, reducing RC levels through the use of various lipid-lowering drugs may yield long-term benefits. Nevertheless, routine testing of RC in clinical practice remains controversial, necessitating further research on the treatment of elevated RC levels to evaluate the advantages of reducing RC in patients at high risk of ASCVD.

show abstract

Development of a Novel Homogeneous Assay for Remnant Lipoprotein Particle Cholesterol

Cited by 18 publications

References 32 publications

Role of apolipoprotein C‐III overproduction in diabetic dyslipidaemia

Role of apolipoprotein C‐III overproduction in diabetic dyslipidaemia

Circadian Rhythm of Subspecies of Low-Density Lipoprotein-Cholesterol and High-Density Lipoprotein-Cholesterol in Healthy Subjects and Patients with Type 2 Diabetes

A significant presence in atherosclerotic cardiovascular disease: Remnant cholesterol: A review

Contact Info

Product

Resources

About